US2016075635A1PendingUtilityA1
Vivo gelling pharmaceutical pre-formulation
Est. expiryMay 7, 2030(~3.8 yrs left)· nominal 20-yr term from priority
A61P 35/00A61P 31/12C08G 65/34A61K 47/34A61K 49/04C07C 229/24A61K 9/0078A61K 9/0002
49
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Provided herein are in vivo gelling pharmaceutical pre-formulations forming biocompatible hydrogel polymers that are polymerized in vivo and kits comprising at least one nucleophilic compound or monomer unit, at least one electrophilic compound or monomer unit, and optionally at least one therapeutic agent. The biocompatible hydrogel polymer is bioabsorbable and releases the therapeutic agent at a target site, avoiding systemic exposure.
Claims
exact text as granted — not AI-modified1 - 83 . (canceled)
84 . A multifunctional nucleophilic monomer comprising a polyol core, wherein the polyol core is selected from the group consisting of
wherein the polyol core is substituted with 3-8 R-groups, wherein R is:
wherein n is 1-200.
85 . The multifunctional nucleophilic monomer of claim 84 , wherein the polyol core is:
86 . The multifunctional nucleophilic monomer of claim 84 , wherein the polyol core is:
87 . The multifunctional nucleophilic monomer of claim 84 , wherein the polyol core is:
88 . The multifunctional nucleophilic monomer of claim 84 , wherein the polyol core is:Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.